SAN DIEGO—Some higher-intensity statin formulations are associated with an increased risk of acute kidney injury (AKI), according to findings presented at Kidney Week 2012.
In a study that identified statin initiators categorized by dosage and formulation over a six-month washout period, J. Bradley Layton, PhD, MSPH, and colleagues at the University of North Carolina in Chapel Hill looked at the association of higher-potency formulations in relation to AKI. They examined a large U.S. insurance claims database, with individual formulations compared with low-dosage simvastatin.
The researchers identified 4,146,507 eligible statin initiators (73.8% lower-dosage formulations), and found that higher-dosage statins showed no increased risk of AKI over lower-dosage statins.
However, higher-dosage atorvastatin and higher-dosage simvastatin were associated with an elevated risk of AKI, whereas lower-dosage atorvastatin and lower-dosage rosuvastatin were associated with a lower risk.
No comments:
Post a Comment
The lowcarb team value your comments. Thank you for taking the time to contribute to our blog. Please note! negative comments and insults from anonymous idiots, with nothing to add to the debate will not be authorised. However, we welcome constructive criticism.
The best of health to you and yours.
Eddie